Shanghai Curegene Pharmaceutical divulges new Mpro inhibitors

Feb. 4, 2025

Shanghai Curegene Pharmaceutical Co. Ltd. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infections (COVID-19).

BioWorld Science Infection Coronavirus Patents

Today's news in brief

BioWorld

BioWorld briefs for March 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 17, 2025

Clinical trial fraud ends with guilty pleas

BioWorld

In another real-life episode of “sponsor beware,” the owners of a clinical research facility pleaded guilty March 10 in U.S. district court to fraud charges...

At CROI, HIV cure trials raise hopes for broader applicability

BioWorld

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...

Hummingbird migrates ADCs, tech to newco Callio’s $187M debut

BioWorld

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...